Search results for "Systemic"

showing 10 items of 757 documents

Development and validation of the mastocytosis quality of life questionnaire: MC-QoL

2016

Background Mastocytosis is a heterogeneous disease characterized by a clonal expansion of mast cells in various organs. The vast majority of patients affected suffer from signs and symptoms caused by mediator release from mast cells. Although the disease burden is high, there is currently no specific instrument to measure health-related quality of life (HRQoL) impairment in patients with mastocytosis. Objective The aim of this study was to develop and validate a disease-specific tool to assess HRQoL impairment in patients with cutaneous and indolent systemic mastocytosis, the Mastocytosis Quality of Life Questionnaire (MC-QoL). Methods Sixty-two potential MC-QoL items were developed in a co…

AdultMalemedicine.medical_specialtyPathologyAdolescentImmunologyDiseaseMediator releaseYoung Adult030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineQuality of lifeSurveys and QuestionnairesInternal medicinemedicineHumansImmunology and AllergyIn patientSystemic mastocytosisDisease burdenAgedFace validityAged 80 and overbusiness.industryReproducibility of ResultsMiddle Agedmedicine.diseasehumanitiesCombined approach030228 respiratory systemPopulation SurveillanceQuality of LifeFemaleFactor Analysis StatisticalbusinessMastocytosisAllergy
researchProduct

A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study.

2015

Objective: Qualitative capillaroscopy patterns in juvenile- and adult-onset systemic sclerosis (SSc) were studied in adulthood using data from the EULAR Scleroderma Trials and Research (EUSTAR) database. Methods: Data collected between June 2004 and April 2013 were examined with focus on capillaroscopy. In this retrospective exploratory study, series of patients with juvenile-onset SSc were matched with series of adult-onset SSc having the same gender and autoantibody profile. Results: 30 of 123 patients with juvenile-onset and 2108 of 7133 with adult-onset SSc had data on capillaroscopy. Juvenile-onset SSc showed scleroderma pattern more frequently than adult-onset SSc (93.3% and 88%). The…

AdultMalemedicine.medical_specialtyPathologyAdolescentKlinikai orvostudományokBiochemistryJuvenile systemic sclerosiSclerodermaMicroscopic AngioscopySystemic sclerosiScleroderma LocalizedYoung AdultMedicineJuvenileHumansYoung adultAge of Onsetskin and connective tissue diseasesChildNailfold CapillaroscopyVideocapillaroscopyAgedRetrospective StudiesEUSTARScleroderma Systemicintegumentary systemCapillaroscopybusiness.industrySimilar distributionMicrocirculationAutoantibodyRetrospective cohort studyOrvostudományokCell BiologyMiddle Agedmedicine.diseaseDermatologyCapillariesNailfold capillaroscopyFemaleAge of onsetCardiology and Cardiovascular MedicinebusinessCapillaroscopy; EUSTAR; Juvenile systemic sclerosis; Microcirculation; Nailfold capillaroscopy; Systemic sclerosis; Videocapillaroscopy; Biochemistry; Cardiology and Cardiovascular Medicine; Cell BiologyMicrovascular research
researchProduct

Thrombotic events in systemic lupus erythematosus. Its association with acquired and inherited thrombophilic defects.

2008

Systemic lupus erythematosus (SLE) is characterised by increased venous and arterial thrombotic risk. Although antiphospholipid antibodies (APAs) have been shown to be related with thrombotic tendency in these patients, in more than 40% of them, thrombosis occurs without the presence of such antibodies. We analysed the association of venous and arterial thrombotic events with acquired (anticardiolipin antibodies (ACAs) and lupus anticoagulant (LA)) and inherited (antithrombin (AT), protein C (PC), protein S (PS) deficiencies, factor V Leiden and the prothrombin G20210A mutation), thrombophilic risk factors in 86 SLE patients and 89 healthy controls. Patients showed a higher significant perc…

AdultMalemedicine.medical_specialtyPhysiologyGastroenterologyProtein SRisk FactorsPhysiology (medical)Internal medicinemedicineFactor V LeidenHumansLupus Erythematosus SystemicRisk factorLupus anticoagulantbiologybusiness.industryAntithrombinThrombosisHematologyBlood ProteinsMiddle Agedmedicine.diseaseThrombosisVenous thrombosisAntibodies AnticardiolipinLupus Coagulation InhibitorImmunologyMutationbiology.proteinFemaleCardiology and Cardiovascular MedicinebusinessProtein Cmedicine.drugClinical hemorheology and microcirculation
researchProduct

Multidisciplinary approach to the complex treatment for non-cirrhotic portal hypertension - case-report-based discussion.

2021

Non-cirrhotic portal vein thrombosis (PVT) in patients with antiphospholipid syndrome (APS) is a rare complication, and the management has to be determined individually based on the extent and severity of the presentation. We report on a 37-year-old male patient with non-cirrhotic chronic PVT related to a severe thrombophilia, comprising APS, antithrombin-, factor V- and factor X-deficiency. Three years after the initial diagnosis of non-cirrhotic PVT, the patient presented with severe hemorrhagic shock related to acute bleeding from esophageal varices, requiring an emergency transjugular intrahepatic portosystemic stent shunt (TIPSS). TIPSS was revised after a recurrent bleeding episode du…

AdultMalemedicine.medical_specialtyPortal venous pressuremedicine.medical_treatment030204 cardiovascular system & hematologyThrombophiliaEsophageal and Gastric Varices03 medical and health sciences0302 clinical medicineEsophageal varicesHypertension PortalmedicineHumansThrombophiliaEmbolizationPatient Care TeamVenous Thrombosisbusiness.industryPortal VeinGastroenterologymedicine.diseaseThrombosisSurgeryPortal vein thrombosisPortal hypertension030211 gastroenterology & hepatologyStentsPortasystemic Shunt Transjugular IntrahepaticbusinessVaricesGastrointestinal HemorrhageZeitschrift fur Gastroenterologie
researchProduct

Lack of association of the -463 G/A myeloperoxidase promoter polymorphism with Behcet's disease in Italian patients.

2007

Objective. To investigate potential associations between the � 463G/A myeloperoxidase (MPO) promoter polymorphism and susceptibility to, and clinical expression of, Behcet's disease (BD). Methods. One hundred and seventy-five Italian patients who satisfied the International Study Group criteria for BD and 235 healthy age- and sex-matched blood donors were genotyped for the �463G/A promoter polymorphism of the MPO gene by molecular methods. The patients were subgrouped according to the presence or absence of clinical manifestations. Results. The distribution of allele and genotype frequencies of the MPO �463A/G polymorphism did not differ significantly between the BD patients and the healthy…

AdultMalemedicine.medical_specialtySystemic diseaseAdult; Behcet Syndrome; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Heterozygote; Histocompatibility Testing; Humans; Male; Peroxidase; Promoter Regions Genetic; Polymorphism GeneticHeterozygoteGenotypeBehcet's diseaseBehçet's disease; Disease manifestation; Myeloperoxidase; Myeloperoxidase gene polymorphism; Adult; Behcet Syndrome; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Heterozygote; Histocompatibility Testing; Humans; Male; Peroxidase; Promoter Regions Genetic; Polymorphism Genetic; Rheumatology; Pharmacology (medical)Promoter RegionsRheumatologyGeneticGene FrequencyInternal medicineGenotypemedicineHumansPharmacology (medical)Genetic Predisposition to DiseaseAllelePolymorphismPromoter Regions GeneticPeroxidasePolymorphism Geneticbiologybusiness.industryBehcet SyndromeHistocompatibility TestingOdds ratiomedicine.diseaseRheumatologyGenotype frequencyMyeloperoxidaseImmunologybiology.proteinFemalebusinessRheumatology (Oxford, England)
researchProduct

Timing of quality of life improvements in psoriatic patients treated with different systemic therapies

2019

Psoriasis impacts the quality of life (QoL) by disrupting overall health and social life. Thus, the use of a QoL evaluation item is crucial in assessing a therapeutic regimen. Also, faster improvements in QoL lead to better patient compliance, but very few studies compare psoriasis traditional and biologic therapies timing. To evaluate how much different systemic therapies improve disease severity and QoL, a retrospective analysis was performed on 56 patients. Subjects were administered different drugs and their vital statistics, psoriasis area severity index (PASI) and PSOdisk were collected at baseline and after 30 days. We found a moderate correlation between PASI and PSOdisk score with …

AdultMalemedicine.medical_specialtyTime FactorsAdolescentAnti-Inflammatory AgentsDermatologySeverity of Illness IndexSocial lifeYoung Adult030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineDisease severityQuality of lifeSurveys and QuestionnairesPsoriasisInternal medicinesystemic therapiesUstekinumabmedicineHumansPsoriasisPatient complianceAgedRetrospective StudiesSkinpsoriasiAged 80 and overTherapeutic regimenbusiness.industryBiologic therapiesAdalimumabGeneral MedicineMiddle Agedmedicine.diseasehumanitiesBiological TherapyTreatment Outcomequality of life030220 oncology & carcinogenesisCyclosporineFemaleUstekinumabDermatologic AgentsbusinessFollow-Up Studiesmedicine.drug
researchProduct

The role of posterior parietal cortices on prismatic adaptation effects on the representation of time intervals

2013

Previous studies provided evidence of an ascending left-to-right spatial representation of time durations by using a technique affecting high levels of spatial cognition, i.e. prismatic adaptation (PA). Indeed, PA that induced a leftward aftereffect distorted time representation toward an underestimation, while PA that induced a rightward aftereffect distorted time representation toward an overestimation. The present study advances previous findings on the effects of PA on time by investigating the neural basis subtending these effects. We focused on the posterior parietal cortex (PPC) since it is involved in the PA procedure and also in the formulation of the spatial representation of time…

AdultMalemedicine.medical_specialtyTime FactorsCognitive NeuroscienceBisectionPosterior parietal cortexExperimental and Cognitive PsychologyAdaptation (eye)AudiologyFunctional LateralityDevelopmental psychologyTask (project management)Young AdultBehavioral NeuroscienceFigural AftereffectParietal LobeReaction TimemedicineHumansSpatial representationTime representationPrismatic adaptationAnalysis of VarianceSettore M-PSI/02 - Psicobiologia E Psicologia FisiologicaRepresentation (systemics)Spatial cognitionSpatial representation of timeAdaptation PhysiologicalTranscranial Magnetic StimulationDuration (music)Space PerceptionTime PerceptionFemaleEye Protective DevicesPsychologyPhotic StimulationPosterior parietal cortex
researchProduct

Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol

2006

Objectives: to evaluate the clinical efficacy and the effects on the quality of life of Iloprost, a prostacyclin analogue, used, according to a new protocol, in patients with Raynaud’s phenomenon secondary to Systemic Sclerosis. Methods: in this randomized study we treated 30 patients with Iloprost given by intravenous infusion, at progressively increasing doses (starting from 0.5 ng/Kg/min up 2 ng/Kg/min) over a period of 6 hours a day for ten days in two consecutive weeks, with repeated cycles at regular intervals of three months for 18 months. The results were compared with those obtained in 30 other patients, who had received the same drug but with different posologic schemes. Results: …

AdultMalemedicine.medical_specialtyTime FactorsVasodilator AgentsSeverity of Illness IndexDrug Administration ScheduleSclerodermalaw.inventionRheumatologyRandomized controlled trialQuality of lifelawSeverity of illnessmedicineHumansPharmacology (medical)IloprostProspective StudiesDosingInfusions IntravenousProspective cohort studySystemic Sclerosis Raynaud's phenomenon Iloprost Quality of lifeScleroderma SystemicDose-Response Relationship DrugVascular diseasebusiness.industryRaynaud DiseaseMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeAnesthesiaQuality of LifeFemalebusinessIloprostmedicine.drugRheumatology
researchProduct

Acute Phase Proteins Are Baseline Predictors of Tuberculosis Treatment Failure

2021

Systemic inflammation is a characteristic feature of pulmonary tuberculosis (PTB). Whether systemic inflammation is associated with treatment failure in PTB is not known. Participants, who were newly diagnosed, sputum smear and culture positive individuals with drug-sensitive PTB, were treated with standard anti-tuberculosis treatment and classified as having treatment failure or microbiological cure. The plasma levels of acute phase proteins were assessed at baseline (pre-treatment). Baseline levels of C-reactive protein (CRP), alpha-2 macroglobulin (a2M), Haptoglobin and serum amyloid P (SAP) were significantly higher in treatment failure compared to cured individuals. ROC curve analysis …

AdultMalemedicine.medical_specialtyTuberculosisImmunologyAntitubercular AgentsSystemic inflammationGastroenterologyCohort StudiesInternal medicinemedicineHumansImmunology and AllergyProspective StudiesTreatment FailureTuberculosis PulmonaryOriginal ResearchHaptoglobinsbiologybusiness.industryHaptoglobinAcute-phase proteinArea under the curveRC581-607Middle Agedmedicine.diseasePregnancy-Associated alpha 2-MacroglobulinsMacroglobulinSerum Amyloid P-ComponentC-Reactive ProteintuberculosisROC CurveinflammationTB treatmentacute phase proteinsbiology.proteinbiomarkerSputumBiomarker (medicine)FemaleImmunologic diseases. Allergymedicine.symptombusinessBiomarkersAcute-Phase ProteinsFrontiers in Immunology
researchProduct

Sudden Sensorineural Hearing Loss: Results of intratympanic steroids as salvage treatment

2012

Objective: The aim of the present study was to verify the efficacy and the safety of intratympanic dexamethasone to treat sudden sensorineural hearing loss as salvage therapy. Materials and methods: A prospective study was conducted on patients affected by idiopathic sudden hearing loss who were treated before with some systemic therapy, but without recovery of the hearing The patients able to undergo the study, but who refused salvage treatment were considered as control group. A solution of Dexamethasone 4 mg/ml was then injected through the posterior–inferior quadrant filling completely the middle ear. The follow-up in the following 6 months included an audiogram every month. Results: Th…

AdultMalemedicine.medical_specialtyTympanic MembraneAdolescentNeurosensorial Hearing Loss Steroids treatmentHearing lossHearing Loss SensorineuralSalvage therapyInjections IntralesionalAudiologyRisk AssessmentSystemic therapyDexamethasoneYoung AdultConfidence IntervalsOdds Ratiootorhinolaryngologic diseasesmedicineHumansProspective StudiesProspective cohort studyDexamethasoneAgedSalvage TherapyAnalysis of VarianceAbsolute threshold of hearingmedicine.diagnostic_testbusiness.industryAudiogramHearing Loss SuddenMiddle AgedTreatment OutcomeSettore MED/31 - OtorinolaringoiatriaOtorhinolaryngologyCase-Control StudiesAnesthesiaAudiometry Pure-ToneFemaleAudiometrymedicine.symptombusinessFollow-Up Studiesmedicine.drugAmerican Journal of Otolaryngology
researchProduct